ClinicalTrials.gg
RecruitingNCT06663813Updated Dec 18, 2024

Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients

An interventional study of Educational Intervention in Type 2 Diabetes and Hyperglycemia, sponsored by Rutgers, The State University of New Jersey. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-18.

Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey — 5 open to participants now, 5 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Rutgers, The State University of New Jersey.

Planned enrollment
Largest of 12
400 · median 54
Started
2024
with 1 other
No phase
11 of 12
4 open now
Registered
8th of 12
by date

Among the 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey, this one has the largest planned enrollment, is one of 2 that started in 2024, is one of 11 with no phase, and was the 8th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey, or all of them as a file.
02

Study summary

The goal of this clinical trial is to increase Type 2 Diabetes Mellitus knowledge and awareness among patients who present to the Emergency Department with hyperglycemia. The main questions it aims to answer are:

  • How do patients view their risk of developing type 2 diabetes based on their demographics and behaviors?
  • Does giving patient education increase patient knowledge, leading to healthier behaviors?

Researchers will assess if the educational intervention increases diabetes knowledge and positive health behaviors among Emergency Department hyperglycemic patients.

Participants will:

  • Receive the educational packet (intervention) alongside standard Emergency Care.
  • Take pre-survey at time of Emergency Department visit and post- survey two weeks later.
Read the detailed description

Despite the large prevalence of patients presenting to the Emergency Department (ED) with hyperglycemia or disease manifestations related to Type 2 Diabetes Mellitus (T2DM), there remains a gap in our understanding of rapid educational strategies delivered within the ED itself. As such, the goal of this project is to utilize the Health Belief Model (HBM) framework to target ED patients' perceived susceptibility, severity, benefits, and barriers in an effort to enhance proactive health behaviors, such as primary care physician (PCP) follow-up and utilization of medication assistance programs, among ED patients.

We will recruit 400 English speaking adults who present to the ED with a blood glucose of ≥200 mg/dL. All participants will receive educational materials on diabetes, as well as resources to local primary-care follow up and medication assistance programs. Participants will complete pre- and post-surveys to quantify changes in self-perceived susceptibility, severity, barriers to managing T2DM, and behavioral changes, which include presence of PCP follow-up, establishing a new PCP, and utilizing medication assistance programs.

Quantitative pre- and post-survey responses will be analyzed via regression models and paired t-tests to evaluate for statistically significant changes in perceived susceptibility, severity, benefits, and barriers to T2DM self-management among participants before and after receiving the educational intervention.The expected findings of this research study are increases in patient diabetes knowledge and self-perception of susceptibility and severity, leading to higher rates of PCP follow-up among participants following dissemination of educational materials grounded in the HBM framework. These research outcomes can be utilized to inform future interventions that target further barriers or reduce ED recidivism for hyperglycemic patients in the ED.

03

Conditions studied

  • Type 2 Diabetes
  • Hyperglycemia

Keywords

  • Emergency Medicine
  • Type 2 Diabetes
  • Hyperglycemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Persons 18 years of age or older who present as patients in the Robert Wood Johnson University Hospital Emergency Department with or without a preexisting Type 2 Diabetes Mellitus diagnosis with a blood glucose of ≥200 mg/dL. Participants must speak English to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Age less than 18 years and blood glucose \<200 mg/dL.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Intervention Arm

    Participants in the intervention arm will receive Type 2 Diabetes Mellitus educational materials that includes information regarding Type 2 Diabetes symptoms, risk factors, and resources for further follow-up care alongside standard Emergency Medicine care, which includes discharge instructions provided by ED practitioners along with verbal explanations from their assigned ED nurse.

    Behavioral: Educational Intervention

Interventions

  • BehavioralEducational Intervention

    Utilizing the Health Belief model, educational materials detailing diabetes risk factors to address perceived susceptibility, diabetes severity and complications to address perceived severity, and PCP follow-up information and medication assistance programs to address perceived barriers will be provided.

06

What researchers measure

Primary outcomes

  1. Diabetes Knowledge

    Changes in self-perceived susceptibility, severity, benefits, and barriers to managing T2DM, aligned with the Health Belief Model

    Time frame: Initial Emergency Department presentation to follow-up survey (2 weeks later)

Secondary outcomes

  1. Proactive and Preventative Health Behaviors

    Behavioral changes, which include presence of PCP follow-up, establishing a new PCP, and utilizing medication assistance programs.

    Time frame: Initial Emergency Department presentation to follow-up survey (2 weeks later)

07

Study locations

2 of 2 sites recruiting
  • One Robert Wood Johnson Place
    New Brunswick, New Jersey 08540, United States
    Recruiting
  • One Robert Wood Johnson Place
    New Brunswick, New Jersey 08901, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — IPD that underlie the results reported in this article, after deidentification (including text, tables, figures, and appendices).

Supporting information: Study protocol

Time frame: Beginning 9 months and ending 36 months following article publication.

Access criteria: Due to the nature of the data being collected, and to ensure participant confidentiality, data will be made available using a tiered request for access system. All tiers of data require a data-use agreement (DUA) at a minimum, additional precautions for restricted-use will be included in data request forms.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2025, 14 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 14 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2024
First posted
Oct 29, 2024
StartActual
Oct 29, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Dec 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06663813
Responsible party
Sara Heinert, PhD, MPH (Co-Director of Research; Assistant Professor at the Department of Emergency Medicine, Rutgers, The State University of New Jersey) — Principal investigator
First posted
Oct 29, 2024
Start date
Oct 29, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Dec 18, 2024

Study contacts

Neha V Maddali, BSPH
Contact
nvm37@rwjms.rutgers.edu
9739758066
Sara Heinert, PhD, MPH
principal investigator · Rutgers Robert Wood Johnson Medical School

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion